Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

And although shares fell 35% from peak-to-trough, it became apparent that those who seek these weight-loss drugs also tend to ...

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $250.00. The ...

Piper Sandler analyst Adam Maeder maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $260.00. The ...

ResMed Inc. (RMD)股价创下了显著的里程碑，飙升至52周新高260.71美元。根据 InvestingPro 分析，这家市值382亿美元的医疗设备巨头保持着强劲的财务健康状况。这一峰值反映了该医疗设备公司的显著上升趋势，其股价在过去一年中增长了36.7%。公司的稳健表现得到了9.9%的稳定收入增长和连续13年的稳定派息历史的支持。投资者和市场分析师正密切关注ResMed的表现，因为该 ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

In the last year, many ResMed Inc. ( NYSE:RMD ) insiders sold a substantial stake in the company which may have ...

The S&P 500 (SNPINDEX: ^GSPC) is widely considered the best gauge for the overall U.S. stock market. The index surged 23% in ...

We award ResMed a narrow moat rating based on switching costs and intangible assets, which have helped the company achieve high customer adherence rates and above-average industry growth.

The decline in stock value comes as analysts express mixed views on the company's quarterly performance. While ResMed achieved a 10% revenue increase compared to the same quarter last year, some ...

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.